The introduction of Dengvaxia has been met with some controversy, particularly in the Philippines, where a mass vaccination campaign led to concerns over vaccine safety. Reports of severe dengue cases in vaccinated individuals who were seronegative at the time of vaccination led to public outcry and legal actions. These events underscore the importance of careful post-marketing surveillance and risk communication in vaccine programs.
